News & Updates
Filter by Specialty:
ESK-001 makes good STRIDEs for plaque psoriasis
In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.
ESK-001 makes good STRIDEs for plaque psoriasis
22 Mar 2024Severe COVID-19 rare in PrEP-treated SARDs patients
Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.
Severe COVID-19 rare in PrEP-treated SARDs patients
08 Mar 2024Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
The use of abatacept in adults at high risk of rheumatoid arthritis helps protect against disease onset, as shown in the phase IIB APIPPRA study.
Abatacept may mitigate rheumatoid arthritis development in at-risk individuals
24 Feb 2024Serious infections prevalent in RTX-treated patients with SLE
A recent study has reported the prevalence of serious infection (SI) among patients with systemic lupus erythematosus (SLE) following treatment with rituximab (RTX).
Serious infections prevalent in RTX-treated patients with SLE
13 Feb 2024Is BASDAI a responsive instrument in PsA?
Use of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as an instrument in psoriatic arthritis (PsA) demonstrates “reasonable” responsiveness but falls short of distinguishing peripheral PsA from axial (ax)PsA, according to a recent study.